Literature DB >> 9094607

Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

L V Gubareva1, M J Robinson, R C Bethell, R G Webster.   

Abstract

Here we report the isolation of influenza virus A/turkey/Minnesota/833/80 (H4N2) with a mutation at the catalytic residue of the neuraminidase (NA) active site, rendering it resistant to the novel NA inhibitor 4-guanidino-Neu5Ac2en (GG167). The resistance of the mutant stems from replacement of one of three invariant arginines (Arg 292-->Lys) that are conserved among all viral and bacterial NAs and participate in the conformational change of sialic acid moiety necessary for substrate catalysis. The Lys292 mutant was selected in vitro after 15 passages at increasing concentrations of GG167 (from 0.1 to 1,000 microM), conditions that earlier gave rise to GG167-resistant mutants with a substitution at the framework residue Glu119. Both types of mutants showed similar degrees of resistance in plaque reduction assays, but the Lys292 mutant was more sensitive to the inhibitor in NA inhibition tests than were mutants bearing a substitution at framework residue 119 (Asp, Ala, or Gly). Cross-resistance to other NA inhibitors (4-amino-Neu5Ac2en and Neu5Ac2en) varied among mutants resistant to GG167, being lowest for Lys292 and highest for Asp119. All GG167-resistant mutants demonstrated markedly reduced NA activity, only 3 to 50% of the parental level, depending on the particular amino acid substitution. The catalytic mutant (Lys292) showed a significant change in pH optimum of NA activity, from 5.9 to 5.3. All of the mutant NAs were less stable than the parental enzyme at low pH. Despite their impaired NA activity, the GG167-resistant mutants grew as well as parental virus in Madin-Darby canine kidney cells or in embryonated chicken eggs. However, the infectivity in mice was 500-fold lower for Lys292 than for the parental virus. These findings demonstrate that amino acid substitution in the NA active site at the catalytic or framework residues, followed by multiple passages in vitro, in the presence of increasing concentrations of the NA inhibitor GG167, generates GG167-resistant viruses with reduced NA activity and decreased infectivity in animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094607      PMCID: PMC191482     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.

Authors:  J N Varghese; J L McKimm-Breschkin; J B Caldwell; A A Kortt; P M Colman
Journal:  Proteins       Date:  1992-11

Review 2.  The neuraminidase of influenza virus.

Authors:  G M Air; W G Laver
Journal:  Proteins       Date:  1989

3.  Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution.

Authors:  J N Varghese; W G Laver; P M Colman
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

4.  Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism.

Authors:  M R Lentz; R G Webster; G M Air
Journal:  Biochemistry       Date:  1987-08-25       Impact factor: 3.162

5.  Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action.

Authors:  P Palese; R W Compans
Journal:  J Gen Virol       Date:  1976-10       Impact factor: 3.891

6.  Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.

Authors:  J N Varghese; P M Colman
Journal:  J Mol Biol       Date:  1991-09-20       Impact factor: 5.469

7.  Newcastle disease virus contains a linkage-specific glycoprotein sialidase. Application to the localization of sialic acid residues in N-linked oligosaccharides of alpha 1-acid glycoprotein.

Authors:  J C Paulson; J Weinstein; L Dorland; H van Halbeek; J F Vliegenthart
Journal:  J Biol Chem       Date:  1982-11-10       Impact factor: 5.157

8.  Biologic potential of amantadine-resistant influenza A virus in an avian model.

Authors:  W J Bean; S C Threlkeld; R G Webster
Journal:  J Infect Dis       Date:  1989-06       Impact factor: 5.226

9.  Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.

Authors:  A T Baker; J N Varghese; W G Laver; G M Air; P M Colman
Journal:  Proteins       Date:  1987

10.  Synthesis of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and detection of skin fibroblast neuraminidase in normal humans and in sialidosis.

Authors:  T G Warner; J S O'Brien
Journal:  Biochemistry       Date:  1979-06-26       Impact factor: 3.162

View more
  72 in total

1.  Dose-dependent changes in influenza virus-infected dendritic cells result in increased allogeneic T-cell proliferation at low, but not high, doses of virus.

Authors:  SangKon Oh; J Michael McCaffery; Maryna C Eichelberger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Mutation signature in neuraminidase gene of avian influenza H9N2/G1 in Egypt.

Authors:  Zienab Mosaad; Abdelsatar Arafa; Hussein A Hussein; Mohamed A Shalaby
Journal:  Virusdisease       Date:  2017-05-23

3.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

Review 4.  Oseltamivir.

Authors:  A Bardsley-Elliot; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

5.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

6.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

Review 7.  Zanamivir.

Authors:  S L Waghorn; K L Goa
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

8.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

9.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

10.  How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.

Authors:  Andreas Handel; Victoria Akin; Sergei S Pilyugin; Veronika Zarnitsyna; Rustom Antia
Journal:  J R Soc Interface       Date:  2014-01-15       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.